Wedbush lowered the firm’s price target on Xencor (XNCR) to $31 from $38 and keeps an Outperform rating on the shares. The firm notes that the company has announced earnings and disclosed a pause of vudalimab development. Wedbush’s focus in the near-term shifts toward XmAb942, for which Xencor expects first healthy volunteer SAD results in the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor’s Strategic Advancements and Financial Strength Signal Positive Outlook
- Xencor price target lowered to $32 from $34 at RBC Capital
- Promising Pipeline and Innovative Platforms Drive Buy Rating for Xencor
- Xencor price target lowered to $33 from $37 at Wells Fargo
- Strategic Shift and Promising Pipeline: Xencor’s Growth Potential and Investment Opportunity
Questions or Comments about the article? Write to editor@tipranks.com